Nikolaos Ziras

FOLFOXIRI (folinic acid, 5-fluorouracil, oxaliplatin and irinotecan) vs FOLFIRI (folinic acid, 5-fluorouracil and irinotecan) as first-line treatment in metastatic colorectal cancer (MCC): a multicentre randomised phase III trial from the Hellenic Oncology Research Group (HORG)

John Souglakos, N. Androulakis, K. Syrigos et al. · British Journal of Cancer · 2006 · 399 citations · Full text

A multicenter phase III trial comparing irinotecan-gemcitabine (IG) with gemcitabine (G) monotherapy as first-line treatment in patients with locally advanced or metastatic pancreatic cancer

G. Stathopoulos, K. Syrigos, Gerasimos Aravantinos et al. · British Journal of Cancer · 2006 · 196 citations · Full text

Urology, Pancreatic Cancer, Gemcitabine Monotherapy +15

Six versus 12 months of adjuvant trastuzumab in combination with dose-dense chemotherapy for women with HER2-positive breast cancer: a multicenter randomized study by the Hellenic Oncology Research Group (HORG)

D. Mavroudis, Emmanouil Saloustros, N. Malamos et al. · Annals of Oncology · 2015 · 162 citations

Breast Oncology, Oncology, Dose-dense Chemotherapy +6

Phase II study of liposomal cisplatin (Lipoplatin™) plus gemcitabine versus cisplatin plus gemcitabine as first line treatment in inoperable (stage IIIB/IV) non-small cell lung cancer

N. Mylonakis, A E Athanasiou, Nikolaos Ziras et al. · Lung Cancer · 2009 · 96 citations

Liposomal Cisplatin, Medicine, Pathology +7

Weekly chemotherapy with docetaxel, gemcitabine and cisplatin in advanced transitional cell urothelial cancer: a phase II trial

D. Pectasides, John Glotsos, N Bountouroglou et al. · Annals of Oncology · 2002 · 59 citations · Full text

Urology, Phase Ii Trial, Genitourinary Cancer +4